Loading
companiesCompany
Checkpoint Therapeutics
Checkpoint Therapeutics developed cosibelimab, an anti-PD-L1 antibody approved by the FDA in December 2024 for advanced cutaneous squamous cell carcinoma, and was acquired by Sun Pharma in 2025.
Also called: Checkpoint Therapeutics, Inc.
Overview
Checkpoint Therapeutics, a Massachusetts company founded within Fortress Biotech, developed cosibelimab (Unloxcyt), an anti-PD-L1 antibody with an intact Fc region designed to add antibody-dependent cell killing to checkpoint blockade. The FDA approved it in December 2024 for metastatic or locally advanced cutaneous squamous cell carcinoma not curable by surgery or radiation, after an earlier complete response letter over a manufacturing site. Sun Pharma agreed to acquire the company in 2025. Company facts are from the official website and FDA approval records.
Headquarters
Waltham, MA, US
Scorecard
All companies#284of 1244 companies, score 15
- approved products +6
- targets +2
- modalities +2
- regions +1
- 24-month regulatory events +2
- registry trials +2
1 approved, 0 in phase 3, 0 earlier, 1 targets, 1 registry studies. Formula on the scorecards page.
Type
Stage
Acquired
ApprovedAnti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)
Cosibelimab · Unloxcyt
Cosibelimab is a PD-L1 antibody approved in December 2024 for advanced cutaneous squamous cell carcinoma, offering a third immunotherapy choice.
Similar pages
- TrialKEYNOTE-629
- TrialC-POST (cemiplimab after surgery and radiotherapy for high-risk skin squamous cell carcinoma)
- CancerAdvanced cutaneous squamous cell carcinoma
Shares Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma, Cosibelimab, CK-301-101, Cutaneous squamous cell carcinoma.
- TrialEMPOWER-CSCC-1
cancers
fronts
drugs
ApprovedAnti-PD-L1 monoclonal antibody (IgG1, ADCC-competent)
Cosibelimab · Unloxcyt